Please login to the form below

Not currently logged in
Email:
Password:

migalastat

This page shows the latest migalastat news and features for those working in and with pharma, biotech and healthcare.

Amicus Therapeutics launches Fabry treatment Galafold in Italy

Amicus Therapeutics launches Fabry treatment Galafold in Italy

US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage.

Latest news

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    The UK's cost-effectiveness regulator has published final guidance endorsing the use of Galafold (migalastat) for Fabry, an inherited lysosomal storage disease caused by deficiency in the enzyme alpha-galactosidase ... At one point migalastat was

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder.

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised Technologies guidance.

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    Amicus Therapeutics got a green light from the CHMP for Galafold (migalastat) as the first oral treatment for Fabry disease, which is caused by a deficiency in alpha-galactosidase A. ... The positive opinion marks a turnaround for migalastat, which had

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity investment of $3m.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics